| Literature DB >> 33235506 |
Xiao-Ying Hu1,2,3,4,5, Dong-Wei Liu1,2,3,4,5, Ying-Jin Qiao1,2,3,4,5, Xuan Zheng6, Jia-Yu Duan1,2,3,4,5, Shao-Kang Pan1,2,3,4,5, Zhang-Sou Liu1,2,3,4,5.
Abstract
PURPOSE: To develop and validate a nomogram model to predict the occurrence of acute kidney disease (AKD) after nephrectomy. PATIENTS AND METHODS: A retrospective cohort including 378 patients with renal cell carcinoma (RCC) who had undergone radical or partial nephrectomy between March 2013 and December 2017 at the First Affiliated Hospital of Zhengzhou University was analyzed. Of these, patients who had undergone surgery in an earlier period of time formed the training cohort (n=265) for nomogram development, and those who had undergone surgery thereafter formed the validation cohort (n=113) to confirm the model's performance. The incidence rate of AKD was measured. Univariate and multivariate logistics regression analysis was used to estimate the independent risk factors associated with AKD. The independent risk factors were incorporated into the nomogram. The accuracy and utility of the nomogram were evaluated by calibration curve and decision curve analysis, respectively.Entities:
Keywords: acute kidney disease; kidney cancer; nephrectomy; nomogram; renal cell carcinoma
Year: 2020 PMID: 33235506 PMCID: PMC7680605 DOI: 10.2147/CMAR.S273244
Source DB: PubMed Journal: Cancer Manag Res ISSN: 1179-1322 Impact factor: 3.989
Baseline Characteristics of the Patients in the Training Cohort and the Validation Cohort
| Variables | Cohort | ||
|---|---|---|---|
| Training | Validation | ||
| N=265 (%) | N=113 (%) | ||
| Age, years | |||
| ≤60 | 177 (66.8) | 73 (64.6) | 0.680 |
| >60 | 88 (33.2) | 40 (35.4) | |
| Gender | |||
| Male | 168 (63.4) | 81 (71.7) | 0.120 |
| Female | 97 (36.6) | 32 (28.3) | |
| Weight, mean (SD), kg | 68.9 (11.5) | 70.3 (11.8) | 0.252 |
| CCI | |||
| <4 | 237 (89.4) | 98 (86.7) | 0.448 |
| ≥4 | 28 (10.6) | 15 (13.3) | |
| Surgery approach | |||
| Radical | 66 (24.9) | 47 (41.6) | |
| Partial | 199 (75.1) | 66 (58.4) | 0.001 |
| Preoperative serum creatinine, mean (SD), μmol/L | 76.7 (55.5) | 73.9 (21.2) | 0.641 |
| Preoperative eGFR, mL/min/1.73 m2 | |||
| ≥90 | 177 (66.8) | 73 (64.6) | |
| 60–89 | 74 (27.9) | 33 (29.2) | 0.895 |
| <60 | 14 (5.3) | 7 (6.2) | |
| Decrement of eGFR mean (SD), mL/min/1.73 m2 | 25.3 (17.1) | 22.8 (15.4) | 0.164 |
| Operating time, hours | |||
| ≤2 | 133 (50.2) | 33 (29.2) | <0.001 |
| >2 | 132 (49.8) | 80 (70.8) | |
| Blood loss, mL | |||
| <150 | 190 (71.7) | 85 (75.2) | 0.481 |
| ≥150 | 75 (28.3) | 28 (24.8) | |
| Intraoperative minimum | |||
| >90 | 86 (32.5) | 33 (29.2) | 0.533 |
| ≤90 | 179 (67.5) | 80 (70.8) | |
| Time of SBP below 90 mmHg in surgery, mean (SD), minutes | 12.7 (20.1) | 9.15 (16.8) | 0.112 |
| Intraoperative urinary volume, mean (SD), mL | 246.0 (193.0) | 269.2 (216.1) | 0.285 |
| Intraoperative fluid intake volume, mean (SD), mL | 1,638.9 (969.0) | 1,734.3 (894.9) | 0.200 |
| Pathological type | |||
| Clear cell | 204 (77.0) | 92 (81.4) | 0.096 |
| Papillary cell | 9 (3.4) | 8 (7.1) | |
| Chromophobe renal cell | 13 (4.9) | 5 (4.4) | |
| Others | 39 (14.7) | 8 (7.1) | |
| Tumor number | |||
| Solitary | 253 (95.5) | 111 (98.2) | 0.246 |
| Multiple | 12 (4.5) | 2 (1.8) | |
| Renal capsule invasion | |||
| No | 249 (94.0) | 111 (98.2) | 0.074 |
| Yes | 16 (6.0) | 2 (1.8) | |
| Venous tumor thrombus | |||
| No | 248 (93.6) | 107 (94.7) | 0.681 |
| Yes | 17 (6.4) | 6 (5.3) | |
| TNM stage | |||
| I–II | 215 (81.1) | 97 (85.8) | 0.270 |
| III–IV | 50 (18.9) | 16 (14.2) | |
Notes: Continuous variables are displayed as median (standard deviation); Categorical variables are displayed as number (percentage).
Abbreviations: SD, standard deviation; CCI, Charlson comorbidity index; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure.
Univariate Logistic Regression Analysis of AKD Based on Perioperative Data in the Training Cohort
| Variables | OR (95% CI) | |
|---|---|---|
| Age, >60 vs ≤60, years | 1.37 (0.78–2.40) | 0.273 |
| Gender, male vs female | 0.73 (0.41–1.30) | 0.289 |
| Weight, kg | 1.03 (1.00–1.05) | 0.026 |
| CCI, ≥4 vs <4 | 2.16 (0.97–4.83) | 0.060 |
| Surgery approach, radical vs partial | 4.18 (1.81–9.66) | 0.001 |
| Preoperative serum creatinine, μmol/L | 1.00 (1.00–1.01) | 0.546 |
| Preoperative eGFR, mL/min/1.73 m2 | ||
| 60–89 vs ≥90 | 0.92 (0.50–1.68) | 0.775 |
| <60 vs ≥90 | 0.41 (0.09–1.91) | 0.256 |
| Decrement of eGFR, mL/min/1.73 m2 | 1.06 (1.04–1.08) | <0.001 |
| Operating time, >2 vs ≤2 hours | 0.84 (0.49–1.44) | 0.516 |
| Blood loss, ≥150 vs <150, mL | 0.57 (0.30–1.08) | 0.086 |
| Intraoperative minimum SBP, ≤90 vs >90, mmHg | 1.07 (0.60–1.90) | 0.839 |
| Time of SBP below 90 mmHg in surgery, minutes | 1.00 (0.99–1.01) | 0.497 |
| Pathological type | ||
| Papillary cell vs clear cell | 0.29 (0.04–2.39) | 0.252 |
| Chromophobe renal cell vs clear cell | 0.70 (0.19–2.65) | 0.602 |
| Others vs clear cell | 0.61 (0.26–1.39) | 0.237 |
| Tumor number, multiple vs solitary | 2.78 (0.87–8.91) | 0.086 |
| Renal capsule invasion, yes vs no | 0.59 (0.16–2.13) | 0.421 |
| Venous tumor thrombus, yes vs no | 0.33 (0.07–1.49) | 0.150 |
Abbreviations: OR, odds ratio; CI, confidence interval; CCI, Charlson comorbidity index; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure.
Multivariate Logistic Regression Analysis of AKD Based on Data in the Training Cohort
| Variables | OR (95% CI) | |
|---|---|---|
| Weight, kg | 1.02 (0.99–1.05) | 0.122 |
| Surgery approach, radical vs partial | 3.47 (1.40–8.59) | 0.007 |
| CCI, <4 vs ≥4 | 4.75 (1.75–12.87) | 0.002 |
| Decrement of GFR, mL/min/1.73 m2 | 1.06 (1.03–1.08) | <0.001 |
| Blood loss, ≥150 vs <150, mL | 0.50 (0.24–1.05) | 0.067 |
| Tumor number, multiple vs solitary | 3.13 (0.77–12.78) | 0.112 |
Abbreviations: OR, odds ratio; CI, confidence interval; CCI, Charlson comorbidity index; eGFR, estimated glomerular filtration rate.
Multivariate Logistic Regression Analysis of AKD Based on Variables in the Nomogram
| Variables | OR (95% CI) | |
|---|---|---|
| Surgery approach, radical vs partial | 3.21 (1.31–7.88) | 0.011 |
| CCI, <4 vs ≥4 | 4.62 (1.75–12.18) | 0.002 |
| Decrement of eGFR, mL/min/1.73 m2 | 1.06 (1.04–1.08) | <0.001 |
Abbreviations: OR, odds ratio; CI, confidence interval; CCI, Charlson comorbidity index; eGFR, estimated glomerular filtration rate.
Figure 1Nomogram for the prediction of AKD in patients with RCC within the 3 months after surgery, based on multivariable model. Instructions: locate the surgery approach on the corresponding axis. Draw a line straight down to the axis to calculate how many points toward the probability of AKD in the patients undergoing his/her surgery approach. Repeat the courses for CCI and the decrement of eGFR. Add all points obtained from the previous steps, and locate the final summation on the total score axis. The probability of the AKD corresponds to the summation score on the risk scale.
Figure 2Calibration curve for postoperative AKD based on the nomogram. (A) training cohort, (B) validation cohort. The blue dashed line represents the ideal line of a perfect match between predicted and observed occurrence of AKD. The red line indicates the performance of the proposed nomogram.
Figure 3Decision curve of the nomogram and simple models. (A) Training cohort, (B) Validation cohort. Decision curve analyses demonstrating the net benefit associated with the use of different models for the prediction of postoperative AKD. The thick black line represents the net benefit of offering no intervention, assuming that none of the patients would develop AKD; the blue line shows the net benefit of offering interventions to all patients, assuming that all patients would develop AKD; Other lines represent the net benefit of offering interventions according to different models.